a) Nishimura H, et al. A new methodology for studying dynamics of aerosol particles in sneeze and cough using a digital high-vision, high-speed video system and vector analyses. PLoS One. 2013;8:e80244.
咳のみかた、考えかた
商品紹介
院内でそれを聴かない日はないといってよいほどごくありふれた臨床症状でありながら、患者さんのQOLに大きく影響し、さまざまな疾患の可能性を内包している厄介な「咳」の診療についてまとめた本です。咳を診療する前の鉄則、咳の診断ツール、各疾患の各論、鎮咳薬の使い方、実際の戦略の組み立て、著者が出会った珍しい咳嗽など、「咳」についてあらゆる角度から徹底的に解説を行いました。
目次
- 咳のみかた、考えかた
―目次―
第1章 咳嗽とは何なのか
第2章 咳嗽の概論
第3章 咳嗽を診療する前の鉄則
第4章 咳嗽の診断ツール
第5章 急性咳嗽疾患
第6章 遅延性咳嗽・慢性咳嗽疾患各論
第7章 非特異的鎮咳薬
第8章 実際の戦略の組み立て
第9章 珍しい咳嗽たち
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
第1章 咳嗽とは何なのか
P.4 掲載の参考文献
P.11 掲載の参考文献
a) Kim SY, et al. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015 Sep 21:CD006362.
b) Ishiura Y, et al. COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma. J Investig Allergol Clin Immunol. 2009;19:370-4.
P.14 掲載の参考文献
1) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
2) Morice AH, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007;29:1256-76.
3) Braga PC, Allega L, editors. Cough. New York:Raven Press;1989. p.29-36.
4) Morice AH, et al. Recommendations for the management of cough in adults. Thorax. 2006;61 Suppl 1:i1-24.
5) Gibson PG, et al. CICADA:Cough in Children and Adults:Diagnosis and Assessment. Australian cough guidelines summary statement. Med J Aust. 2010;192:265-71.
6) Asthma Workgroup, Chinese Society, Respiratory, Diseases(CSRD), Chinese Medical, Association. The Chinese national guidelines on diagnosis and management of cough(December 2010). Chin Med J(Engl). 2011;124:3207-19.
7) Rhee CK, et al. The Korean Cough Guideline:Recommendation and summary statement. Tuberc Respir Dis(Seoul). 2016;79:14-21.
8) Chung KF, et al. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008;371:1364-74.
9) Widdicombe JG. Neurophysiology of the cough reflex. Eur Respir J. 1995;8:1193-202.
10) Polverino M, et al. Anatomy and neuro-pathophysiology of the cough reflex arc. Multidiscip Respir Med. 2012;7:5.
11) Groneberg DA, et al. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med. 2004;170:1276-80.
12) Abdullah H, et al. Rhinovirus upregulates transient receptor potential channels in a human neuronal cell line:implications for respiratory virus-induced cough reflex sensitivity. Thorax. 2014;69:46-54.
13) Khalid S, et al. Transient receptor potential vanilloid 1(TRPV1)antagonism in patients with refractory chronic cough:a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134:56-62.
14) Fernandez-Carvajal A, et al. New strategies to develop novel pain therapies:addressing thermoreceptors from different points of view. Pharmaceuticals(Basel). 2011;5:16-48.
15) 田中繁宏. アスリートと咳(慢性咳嗽を中心に)-最近の研究の動向-. 健康運動科学. 2010;1:1-6.
16) Pavesi L, et al. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough:a meta-analysis. Chest. 2001;120:1121-8.
17) Bianchi C, et al. Cough peak flow as a predictor of pulmonary morbidity in patients with dysphagia. Am J Phys Med Rehabil. 2012;91:783-8.
18) Birring SS, et al. Development of a symptom specific health status measure for patients with chronic cough:Leicester Cough Questionnaire(LCQ). Thorax. 2003;58:339-43.
19) French CT, et al. Evaluation of a cough-specific quality-of-life questionnaire. Chest. 2002;121:1123-31.
20) Ogawa H, et al. Chronic cough management:dealing with a sensation of mucus in the throat. Respirology. 2013;18:732-3.
第2章 咳嗽の概論
P.16 掲載の参考文献
1) Irwin RS, et al. Diagnosis and management of cough executive summary:ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):1S-23S.
2) Morice AH, et al. Recommendations for the management of cough in adults. Thorax. 2006;61(Suppl 1):i1-24.
3) Jones BF, et al. Duration of cough in acute upper respiratory tract infections. Aust Fam Physician. 2002;31:971-3.
4) Matsumoto H, et al. Prevalence and clinical manifestations of gastro-oesophageal reflux-associated chronic cough in the Japanese population. Cough. 2007;3:1.
5) Kwon NH, et al. Causes and clinical features of subacute cough. Chest. 2006;129:1142-7.
P.18 掲載の参考文献
1) Metlay JP, et al. National trends in the use of antibiotics by primary care physicians for adult patients with cough. Arch Intern Med. 1998;158:1813-8.
2) Centre for Clinical Practice at NICE(UK). Respiratory Tract Infections-Antibiotic Prescribing:Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in Adults and Children in Primary Care. London:National Institute for Health and Clinical Excellence(UK);2008 Jul.
3) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
P.25 掲載の参考文献
1) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
2) Fujimura M, et al. Importance of atopic cough, cough variant asthma and sinobronchial syndrome as causes of chronic cough in the Hokuriku area of Japan. Respirology. 2005;10:201-7.
3) Matsumoto H, et al. Prevalence and clinical manifestations of gastro-oesophageal reflux-associated chronic cough in the Japanese population. Cough. 2007;3:1.
4) Yamasaki A, et al. Cough and asthma diagnosis:physicians' diagnosis and treatment of patients complaining of acute, subacute and chronic cough in rural areas of Japan. Int J Gen Med. 2010;3:101-7.
5) Ishida T, et al. Clinical investigation of postinfectious cough among adult patients with prolonged cough. Nihon Kokyuki Gakkai Zasshi. 2010;48:179-85.
6) Niimi A, et al. Cough variant and cough-predominant asthma are major causes of persistent cough:a multicenter study in Japan. J Asthma. 2013;50:932-7.
7) Irwin RS, et al. Chronic persistent cough in the adult:the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis. 1981;123:413-7.
8) Poe RH, et al. Chronic persistent cough. Experience in diagnosis and outcome using an anatomic diagnostic protocol. Chest. 1989;95:723-8.
9) Irwin RS, et al. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis. 1990;141:640-7.
10) O'Connell F, et al. Capsaicin cough sensitivity decreases with successful treatment of chronic cough. Am J Respir Crit Care Med. 1994;150:374-80.
11) Mello CJ, et al. Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. Arch Intern Med. 1996;156:997-1003.
12) McGarvey LP, et al. Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol. Thorax. 1998;53:738-43.
13) Birring SS, et al. Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med. 2004;169:15-9.
14) Niimi A, et al. Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. Thorax. 2004;59:608-12.
15) Kastelik JA, et al. Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J. 2005;25:235-43.
16) Dabrowska M, et al. Causes of Chronic Cough in Non-smoking Patients. Adv Exp Med Biol. 2015;873:25-33.
17) Joo JH, et al. Clinical features of eosinophilic bronchitis. Korean J Intern Med. 2002;17:31-7.
18) Ma HM, et al. Etiological diagnosis of chronic cough with unknown causes. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26:675-8.
19) Yang ZM, et al. A prospective study on the causes of chronic cough. J Tongji Univ. 2005;26:62-64.
20) Lai KF, et al. Etiology and a diagnostic protocol for patients with chronic cough. Zhonghua Jie He He Hu Xi Za Zhi. 2006;29:96-9.
21) Wang ZH, et al. Etiological diagnosis and specific treatment of chronic cough in 106 patients. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2007;29:665-8.
22) Lu GL, et al. The spectrum and clinical features of causes for chronic cough. Zhonghua Jie He He Hu Xi Za Zhi. 2009;32:422-5.
23) Cao GQ, et al. A multi-center study on clinical and etiological diagnosis of chronic cough in Chongqing City. Chin J Rispir Crit Care. 2009;8:565-8.
24) Si SY, et al. Distribution of causes and clinical features of chronic cough in Shenyang and its surrounding districts. Chin J Tuberc Respir Dis. 2010;33:862-3.
25) Lai K, et al. A prospective, multicenter survey on causes of chronic cough in China. Chest. 2013;143:613-20.
26) Liu WY, et al. The distribution characteristics of etiology of chronic cough in Lanzhou. Zhonghua Jie He He Hu Xi Za Zhi. 2016;39:362-7.
27) Koo HK, et al. Prevalence of chronic cough and possible causes in the general population based on the Korean National Health and Nutrition Examination Survey. Medicine(Baltimore). 2016;95:e4595.
28) Morice AH, et al. A worldwide survey of chronic cough:a manifestation of enhanced somatosensory response. Eur Respir J. 2014;44:1149-55.
29) Rostami-Hodjegan A, et al. The placebo response to citric acid-induced cough:pharmacodynamics and gender differences. Pulm Pharmacol Ther. 2001;14:315-9.
30) Dicpinigaitis PV, et al. The influence of gender on cough reflex sensitivity. Chest. 1998;113:1319-21.
31) Yousaf N, et al. The long term outcome of patients with unexplained chronic cough. Respir Med. 2013;107:408-12.
32) 細井慶太, 他. 初診の遷延性・慢性咳嗽患者における喀痰の出現頻度の検討. 日本呼吸器学会雑誌. 2011;49:181.
33) Barnes P, et al. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N Engl J Med. 1980;303:263-7.
P.26 掲載の参考文献
a) Chamberlain SA, et al. The impact of chronic cough:a cross-sectional European survey. Lung. 2015;193:401-8.
第3章 咳嗽を診療する前の鉄則
P.30 掲載の参考文献
第4章 咳嗽の診断ツール
P.37 掲載の参考文献
a) Inase N, et al. Chronic bird fancier's lung presenting with acute exacerbation due to use of a feather duvet. Intern Med. 2004;43:835-7.
P.46 掲載の参考文献
a) McNamara RM, et al. Utility of the peak expiratory flow rate in the differentiation of acute dyspnea. Cardiac vs pulmonary origin. Chest. 1992;101:129-32.
b) Pollack CV Jr. Utilization of the peak expiratory flow rate in evaluation of acute dyspnea of cardiac or pulmonary origin. Chest. 1993;103:1306-7.
P.58 掲載の参考文献
a) 粒来崇博, 他. 治療により安定した成人気管支喘息患者における強制オッシレーション法を用いた気流制限の評価. アレルギー. 2012;61;184-93.
b) 柴崎篤, 他. モストグラフとスパイロメトリーによる気道狭窄の評価-可逆性試験を用いた検討-. アレルギー. 2013;62:566-73.
P.64 掲載の参考文献
1) Lee KK, et al. A longitudinal assessment of acute cough. Am J Respir Crit Care Med. 2013;187:991-7.
2) Birring SS, et al. Development of a symptom specific health status measure for patients with chronic cough:Leicester Cough Questionnaire(LCQ). Thorax. 2003;58:339-43.
3) French CT, et al. Evaluation of a cough-specific quality-of-life questionnaire. Chest. 2002;121:1123-31.
4) Lai K. Chinese National Guidelines on Diagnosis and Management of Cough:consensus and controversy. J Thorac Dis. 2014;6(Suppl 7):S683-8.
5) Schmit KM, et al. Evaluating cough assessment tools:a systematic review. Chest. 2013;144:1819-26.
6) 亀井三博. 私は咳をこう診てきた. 東京:南山堂;2013.
7) Imagama S, et al. Influence of lumbar kyphosis and back muscle strength on the symptoms of gastroesophageal reflux disease in middle-aged and elderly people. Eur Spine J. 2012;21:2149-57.
8) 日本アレルギー学会. 喘息予防・管理ガイドライン2015. 東京:協和企画;2015.
9) Dweik RA, et al. An official ATS clinical practice guideline:interpretation of exhaled nitric oxide levels(FENO)for clinical applications. Am J Respir Crit Care Med. 2011;184:602-15.
10) Crapo RO, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors. 1999. Am J Respir Crit Care Med. 2000;161:309-29.
11) Sterk PJ, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:53-83.
12) Burke RR, et al. Two ATS recommended protocols for administration of methacholine are not equal. J Asthma. 2009;46:740-4.
13) 町田久典, 他. 慢性咳嗽患者におけるアストグラフとモストグラフの関連について. 口演59. 第63回日本アレルギー学会秋季学術大会, 2013.
14) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
15) Cunha BA. The clinical diagnosis of Mycoplasma pneumoniae:the diagnostic importance of highly elevated serum cold agglutinins. Eur J Clin Microbiol Infect Dis. 2008;27:1017-9.
16) 小児呼吸器感染症診療ガイドライン作成委員会. 小児呼吸器感染症診療ガイドライン2017. 東京:協和企画;2016.
17) Kishimoto T, et al. Assay of Chlamydia pneumoniae-specific IgM antibodies by ELISA method-reduction of non-specific reaction and resetting of serological criteria by measuring IgM antibodies-. Jpn J Infect Dis. 2009;62:260-4.
18) 三河貴裕. 尿中抗原, 抗体検査の使い方. 山本舜悟, 編. あなたも名医! 侮れない肺炎に立ち向かう31の方法. 東京:日本医事新報社;2013.
19) 藤村政樹. 咳嗽の主要原因疾患の鑑別と治療 2)気管支喘息, 咳喘息, アトピー咳嗽. 呼吸器内科. 2016;29:115-22.
20) 藤村政樹, 他. 第77回呼吸器合同北陸地方会. 慢性咳嗽の病態的診断によるアウトカム:治療成績.
第5章 急性咳嗽疾患
P.71 掲載の参考文献
1) Makela MJ, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36:539-42.
2) Heikkinen T, et al. The common cold. Lancet. 2003;361:51-9.
3) van Gageldonk-Lafeber AB, et al. A case-control study of acute respiratory tract infection in general practice patients in The Netherlands. Clin Infect Dis. 2005;41:490-7.
4) Diehr P. Prediction of pneumonia in outpatients with acute cough--a statistical approach. J Chronic Dis. 1984;37:215-25.
5) van Vugt SF, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough:diagnostic study. BMJ. 2013;346:f2450.
6) Andreeva E, et al. Usefulness of C-reactive protein testing in acute cough/respiratory tract infection:an open cluster-randomized clinical trial with C-reactive protein testing in the intervention group. BMC Fam Pract. 2014;15:80.
7) van Vugt S, et al. Incidental chest radiographic findings in adult patients with acute cough. Ann Fam Med. 2012;10:510-5.
8) Llor C, et al. Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum:randomised placebo controlled trial. BMJ. 2013;347:f5762.
9) Smith SM, et al. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2014;3:CD000245.
10) Petersen I, et al. Protective effect of antibiotics against serious complications of common respiratory tract infections:retrospective cohort study with the UK General Practice Research Database. BMJ. 2007;335:982.
11) Stein PD, et al. Clinical characteristics of patients with acute pulmonary embolism:data from PIOPED II. Am J Med. 2007;120:871-9.
12) O'Beirne SL, et al. Chronic Cough and Bilateral Pneumothoraces in a Nonsmoker. Chest. 2016;149:e49-55.
13) Saiphoklang N, et al. Prevalence, clinical manifestations and mortality rate in patients with spontaneous pneumothorax in Thammasat University Hospital. J Med Assoc Thai. 2013;96:1290-7.
第6章 遷延性咳嗽・慢性咳嗽疾患各論
P.86 掲載の参考文献
1) 石田 直, 他. 成人遷延性咳嗽患者における感染後咳嗽の臨床的検討. 日呼吸会誌. 2010;48:179-85.
2) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
3) Yaari E, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest. 1999;115:1254-8.
4) Cornia PB, et al. Does this coughing adolescent or adult patient have pertussis? JAMA. 2010;304:890-6.
5) Theofiles AG, et al. Pertussis outbreak, southeastern Minnesota, 2012. Mayo Clin Proc. 2014;89:1378-88.
6) Crowcroft NS, et al. Recent developments in pertussis. Lancet. 2006;367:1926-36.
7) 小児呼吸器感染症診療ガイドライン作成委員会. 小児呼吸器感染症診療ガイドライン2017. 東京:協和企画;2016.
8) Wang K, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev. 2014;9:CD003257.
9) Mansel JK, et al. Mycoplasma pneumoniae pneumonia. Chest. 1989;95:639-46.
10) Foy HM, et al. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis. 1979;139:681-7.
11) Johnson S. Possibly autoantibody complications in Mycoplasma pneumoniae infection. Clin Infect Dis. 2006;43:1246.
12) Fujimura M, et al. Cough receptor sensitivity to capsaicin and tartaric acid in patients with Mycoplasma pneumonia. Lung. 1998;176:281-8.
13) 上田剛士. ジェネラリストのための内科診断リファレンス:エビデンスに基づく究極の診断学をめざして. 東京:医学書院;2014.
14) 日本呼吸器学会市中肺炎診療ガイドライン作成委員会, 編. 呼吸器感染症に関するガイドライン. 成人市中肺炎診療ガイドライン. 2007.
15) Grayston JT, et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986;315:161-8.
16) Marrie TJ, et al. Ambulatory patients with community-acquired pneumonia:the frequency of atypical agents and clinical course. Am J Med. 1996;101:508-15.
17) Grayston JT, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis. 1993;168:1231-5.
18) Kishimoto T, et al. Assay of Chlamydia pneumoniae-specific IgM antibodies by ELISA method-reduction of non-specific reaction and resetting of serological criteria by measuring IgM antibodies-. Jpn J Infect Dis. 2009;62:260-4.
19) Miyashita N, et al. Evaluation of serological tests for diagnosis of Chlamydophila pneumoniae pneumonia in patients with nursing and healthcare-associated pneumonia. J Infect Chemother. 2013;19:249-55.
20) Miyashita N, et al. Chlamydophila pneumoniae serology:cross-reaction with Mycoplasma pneumoniae infection. J Infect Chemother. 2013;19:256-60.
21) Mizooka M, et al. Prevalence of chlamydia pneumoniae in Japanese rural districts;association of smoking and physical activity with Chlamydia pneumoniae seropositivity. Intern Med. 2003;42:960-6.
22) Miyashita N, et al. Antibody responses of Chlamydophila pneumoniae pneumonia:Why is the diagnosis of C. pneumoniae pneumonia difficult? J Infect Chemother. 2015;21:497-501.
P.93 掲載の参考文献
1) 鈴木 貴, 他. 活動性肺結核患者における咳関連QOL の検討. 石川:第17回日本咳嗽研究会;2015. p.8-9.
2) Miller L, et al. Sex steroid hormones and macrophage function. Life Sci. 1996;59:1-14.
3) Jain R, et al. Sex hormone-dependent regulation of cilia beat frequency in airway epithelium. Am J Respir Cell Mol Biol. 2012;46:446-53.
4) Chalermskulrat W, et al. Nontuberculous mycobacteria in women, young and old. Clin Chest Med. 2002;23:675-86.
5) 小橋吉博, 他. MAC 感染症の診断に対するキャピリアMAC 抗体ELISA法の臨床評価. 感染症誌. 2012;86:678.
6) Kitada S, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2008;177:793-7.
7) Kitada S, et al. Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA. Eur Respir J. 2013;42:454-60.
P.102 掲載の参考文献
1) Hansen S, et al. Gender differences in adult-onset asthma:results from the Swiss SAPALDIA cohort study. Eur Respir J. 2015;46:1011-20.
2) 日本アレルギー学会. 喘息予防・管理ガイドライン2015. 東京:協和企画;2015.
3) Global Strategy for Asthma Management and Prevention Updated 2017. available from:ginasthma. org.
P.108 掲載の参考文献
1) Corrao WM, et al. Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med. 1979;300:633-7.
2) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
3) Takemura M, et al. Atopic features of cough variant asthma and classic asthma with wheezing. Clin Exp Allergy. 2007;37:1833-9.
4) Shimoda T, et al. The fractional exhaled nitric oxide and serum high sensitivity C-reactive protein levels in cough variant asthma and typical bronchial asthma. Allergol Int. 2013;62:251-7.
5) Niimi A, et al. Eosinophilic inflammation in cough variant asthma. Eur Respir J. 1998;11:1064-9.
6) Sano T, et al. A preliminary study of PEFR monitoring in patients with chronic cough. Lung. 2004;182:285-95.
7) Maniscalco M, et al. Extended analysis of exhaled and nasal nitric oxide for the evaluation of chronic cough. Respir Med. 2015;109:970-4.
8) Chatkin JM, et al. Exhaled nitric oxide as a noninvasive assessment of chronic cough. Am J Respir Crit Care Med. 1999;159:1810-3.
9) Irwin RS, et al. Interpretation of positive results of a methacholine inhalation challenge and 1 week of inhaled bronchodilator use in diagnosing and treating cough-variant asthma. Arch Intern Med. 1997;157:1981-7.
10) Ohkura N, et al. Heightened cough response to bronchoconstriction in cough variant asthma. Respirology. 2012;17:964-8.
11) 藤村政樹. 咳嗽の主要原因疾患の鑑別と治療2)気管支喘息, 咳喘息, アトピー, 咳嗽. 呼吸器内科. 2016;29:115-22.
12) 藤村政樹, 他. 第77回呼吸器合同北陸地方会. 慢性咳嗽の病態的診断によるアウトカム:治療成績.
13) Dicpinigaitis PV, et al. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma. 2002;39:291-7.
14) Spector SL, et al. Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol. 2004;93:232-6.
15) Matsumoto H, et al. Prognosis of cough variant asthma:a retrospective analysis. J Asthma. 2006;43:131-5.
16) Nakajima T, et al. Characteristics of patients with chronic cough who developed classic asthma during the course of cough variant asthma:a longitudinal study. Respiration. 2005;72:606-11.
17) Fujimura M, et al. Predictors for typical asthma onset from cough variant asthma. J Asthma. 2005;42:107-11.
18) Fujimura M, et al. Comparison of atopic cough with cough variant asthma:is atopic cough a precursor of asthma? Thorax. 2003;58:14-8.
19) Matsuoka H, et al. Inflammatory subtypes in cough-variant asthma:association with maintenance doses of inhaled corticosteroids. Chest. 2010;138:1418-25.
P.115 掲載の参考文献
1) 藤村政樹. アトピー素因を有する咳嗽患者の臨床像-いわゆるアレルギー性気管支炎-. アレルギーの臨床. 1989;9:66-9.
2) Ohkura N, et al. Bronchoconstriction-triggered cough in atopic cough:A retrospective study. Exp Lung Res. 2016 23:1-5.
3) Ogawa H, et al. Atopic cough and fungal allergy. J Thorac Dis. 2014;6(Suppl 7):S689-98.
4) Kamei J, et al. Atopic cough-like cough hypersensitivity caused by active sensitization with protein fraction of Aspergillus restrictus strain A-17. Pulm Pharmacol Ther. 2008;21:356-9.
5) Fujimura M, et al. Female gender as a determinant of cough threshold to inhaled capsaicin. Eur Respir J. 1996;9:1624-6.
6) Fujimura M, et al. Exhaled nitric oxide levels in patients with atopic cough and cough variant asthma. Respirology. 2008;13:359-64.
7) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
8) Fujimura M, et al. Comparison of atopic cough with cough variant asthma:is atopic cough a precursor of asthma? Thorax. 2003;58:14-8.
9) Kita T, et al. Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergol Int. 2010;59:185-92.
10) Ogawa H, et al. Treatment of atopic cough caused by Basidiomycetes antigen with low-dose itraconazol. Lung. 2004;182:279-84.
P.120 掲載の参考文献
1) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会編:咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
2) Gibson PG, et al. Chronic cough:eosinophilic bronchitis without asthma. Lancet. 1989;1(8651):1346-8.
3) Lai KF, et al. Etiology and a diagnostic protocol for patients with chronic cough. Zhonghua Jie He He Hu Xi Za Zhi. 2006;29:96-9.
4) Lai K, et al. A prospective, multicenter survey on causes of chronic cough in China. Chest. 2013;143:613-20.
5) Brightling CE, et al. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med. 1999;160:406-10.
6) Brightling CE, et al. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med. 2000;162:878-82.
7) 藤村政樹, 編. 慢性咳嗽を診る. 東京:医薬ジャーナル社;2010.
8) Cai C, et al. Add-on montelukast vs double-dose budesonide in nonasthmatic eosinophilic bronchitis:a pilot study. Respir Med. 2012;106:1369-75.
9) Bao W, et al. Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis:the additive effect on airway inflammation, cough and life quality. Chin Med J(Engl). 2015 5;128:39-45.
10) Lai K, et al. Will nonasthmatic eosinophilic bronchitis develop chronic airway obstruction?:a prospective, observational study. Chest. 2015;148:887-94.
11) Hancox RJ, et al. Eosinophilic bronchitis. Lancet. 2001;358:1104.
12) Berry MA, et al. Observational study of the natural history of eosinophilic bronchitis. Clin Exp Allergy. 2005;35:598-601.
P.122 掲載の参考文献
1) Kita T, et al. Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergol Int. 2010;59:185-92.
2) Fujimura M, et al. Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy. 2000;30:41-7.
3) Shioya T, et al. Antitussive effects of the H1-receptor antagonist epinastine in patients with atopic cough(eosinophilic bronchitis). Arzneimittelforschung. 2004;54:207-12.
4) Nakajima T, et al. Cough sensitivity in pure cough variant asthma elicited using continuous capsaicin inhalation. Allergol Int. 2006;55:149-55.
5) 藤村政樹, 編. 慢性咳嗽を診る. 東京:医薬ジャーナル社;2010.
P.130 掲載の参考文献
1) Greenberg SD, et al. Comparative morphology of chronic bronchitis and chronic sinusitis, with discussion of "Sinobronchial" syndrome. South Med J. 1966;59:64-74.
2) Kadowaki T, et al. An analysis of etiology, causal pathogens, imaging patterns, and treatment of Japanese patients with bronchiectasis. Respir Investig. 2015;53:37-44.
3) Tamaoki J, et al. Impairment of airway mucociliary transport in patients with sinobronchial syndrome:role of nitric oxide. J Aerosol Med. 2000;13:239-44.
4) Chan SC, et al. Shed syndecan-1 restricts neutrophil elastase from alpha1-antitrypsin in neutrophilic airway inflammation. Am J Respir Cell Mol Biol. 2009;41:620-8.
5) Rudmik L, et al. Medical Therapies for Adult Chronic Sinusitis:A Systematic Review. JAMA. 2015;314:926-39.
6) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
7) Kudoh S, et al. Diffuse panbronchiolitis. Clin Chest Med. 2012;33:297-305.
8) Sugiyama Y, et al. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1990;141:1459-62.
9) McDonnell MJ, et al. Non cystic fibrosis bronchiectasis:A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med. 2015;109:716-26.
10) Polverino E, et al. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. J Infect. 2015;71:28-36.
11) Tsuji T, et al. Nontuberculous mycobacteria in diffuse panbronchiolitis. Respirology. 2015;20:80-6.
12) Martinez-Garcia MA, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565-72.
13) Park J, et al. Factors associated with radiologic progression of non-cystic fibrosis bronchiectasis during long-term follow-up. Respirology. 2016;21:1049-54.
14) Welsh EJ, et al. Interventions for bronchiectasis:an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2015 14;7:CD010337.
15) Mertens TC, et al. Azithromycin differentially affects the IL-13-induced expression profile in human bronchial epithelial cells. Pulm Pharmacol Ther. 2016;39:14-20.
16) Tanabe T, et al. Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells. Am J Respir Cell Mol Biol. 2011;45:1075-83.
17) Serisier DJ, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis:the BLESS randomized controlled trial. JAMA. 2013;309:1260-7.
18) Wong C, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis(EMBRACE):a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7.
19) Brodt AM, et al. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis:a systematic review. Eur Respir J. 2014;44:382-93.
20) Orriols R, et al. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respiration. 2015;90:299-305.
21) 水上絵理, 他. 咳嗽の主要原因疾患の鑑別と治療4)慢性気道感染症:副鼻腔気管支症候群を中心に. 呼吸器内科. 2016;29:130-5.
22) Head K, et al. Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011994.
23) Kudoh S, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-32.
24) van den Berg JW, et al. Limited evidence:higher efficacy of nasal saline irrigation over nasal saline spray in chronic rhinosinusitis--an update and reanalysis of the evidence base. Otolaryngol Head Neck Surg. 2014;150:16-21.
25) 日本耳鼻咽喉科感染症・エアロゾル学会, 編. 急性鼻副鼻腔炎に対するネブライザー療法の手引き2016年版. 東京:金原出版;2016.
P.132 掲載の参考文献
a) Tateda K, et al. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides:a promising strategy or an oriental mystery? J Infect Chemother. 2007;13:357-67.
b) Yamasaki T, et al. Effect of antimicrobial agents on the piliation of Pseudomonas aeruginosa and adherence to mouse tracheal epithelium. J Chemother. 1997;9:32-7.
P.138 掲載の参考文献
1) Yu L, et al. Advances in upper airway cough syndrome. Kaohsiung J Med Sci. 2015;31:223-8.
2) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪;メディカルレビュー社;2012.
3) Rudmik L, et al. Medical Therapies for Adult Chronic Sinusitis:A Systematic Review. JAMA. 2015;314:926-39.
4) 鼻アレルギー診療ガイドライン作成委員会. 鼻アレルギー診療ガイドライン-通年性鼻炎と花粉症2016年版. 東京:ライフ・サイエンス;2015.
5) Lai K. Chinese National Guidelines on diagnosis and management of cough:consensus and controversy. J Thorac Dis. 2014;6(Suppl 7):S683-8.
P.143 掲載の参考文献
1) Tokunaga T, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis:the JESREC Study. Allergy. 2015;70:995-1003.
2) 藤枝重治, 他. 好酸球性副鼻腔炎:診断ガイドライン(JESREC Study). 日本耳鼻咽喉科学会会報. 2015;118:728-35.
3) 難病情報センター. 好酸球性副鼻腔炎. http://nanbyou.or.jp/entry/4538
P.150 掲載の参考文献
1) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
2) Morice AH, et al. Cough hypersensitivity syndrome:a distinct clinical entity. Lung. 2011;189:73-9.
3) Everett CF, et al. Clinical history in gastroesophageal cough. Respir Med. 2007;101:345-8.
4) Kusano M, et al. Development and evaluation of FSSG:frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888-91.
5) 高田和外, 他. F スケール質問票を用いた胃食道逆流症の評価とCOPD との関連性の検討. 日呼吸会誌. 2010;48:644-8.
6) Hurst JR, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-38.
7) Ozdemir P, et al. The Role of Microaspiration in the Pathogenesis of Gastroesophageal Reflux-related Chronic Cough. J Neurogastroenterol Motil. 2017;23:41-8.
8) Chang AB, et al. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006;332:11-7.
9) Chang AB, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev. 2011;(1):CD004823.
10) Kahrilas PJ, et al. Chronic Cough due to Gastroesophageal Reflux in Adults:CHEST Guideline and Expert Panel Report. Chest. 2016;150:1341-60.
11) Johnstone J, et al. Meta-analysis:proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31:1165-77.
12) Eom CS, et al. Use of acid-suppressive drugs and risk of pneumonia:a systematic review and meta-analysis. CMAJ. 2011;183:310-9.
13) Giuliano C, et al. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5:337-44.
14) Lambert AA, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy:a systematic review and meta-analysis. PLoS One. 2015;10:e0128004.
15) Morice AH, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J. 2014;44:1132-48.
16) Baumeler L, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016;21:883-90.
17) Sultan N, et al. Association between proton pump inhibitors and respiratory infections:a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22:761-6.
18) Matsumoto H, et al. Prevalence and clinical manifestations of gastro-oesophageal reflux-associated chronic cough in the Japanese population. Cough. 2007;3:1.
19) Dilawari JB, et al. Action of oral metoclopramide on the gastrooesophageal junction in man. Gut. 1973;14:380-2.
20) Howard FA, et al. Effect of metoclopramide on gastric emptying during labour. Br Med J. 1973;1:446-8.
21) Mikami H, et al. Effects of Metoclopramide on Esophageal Motor Activity and Esophagogastric Junction Compliance in Healthy Volunteers. J Neurogastroenterol Motil. 2016;22:112-7.
22) Sontag SJ, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology. 1990;99:613-20.
23) Iliaz S, et al. Does gastroesophageal reflux increase chronic obstructive pulmonary disease exacerbations? Respir Med. 2016;115:20-5.
24) Goldsobel AB, et al. The adult with chronic cough. J Allergy Clin Immunol. 2012;130:825. e6.
25) Johns MW. A new method for measuring daytime sleepiness:the Epworth sleepiness scale. Sleep. 1991;14:540-5.
P.151 掲載の参考文献
a) Lavorini F, et al. Respiratory expulsive efforts evoked by maximal lung emptying. Chest. 2011;140:690-6.
b) Lavorini F, et al. The clinical value of deflation cough in chronic coughers with reflux symptoms. Chest. 2016;149:1467-72.
P.156 掲載の参考文献
1) 日本呼吸器学会COPD ガイドライン第4版作成委員会, 編. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン. 第4版. 東京:メディカルレビュー社;2013.
2) Global Strategy for the Diagnosis, Management and Prevention of COPD, GOLD. 2017.
P.162 掲載の参考文献
1) Mitchell SL, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361:1529-38.
2) 日本摂食嚥下リハビリテーション学会医療検討委員会. 摂食嚥下障害の評価【簡易版】2015. (http://www.jsdr.or.jp/doc/doc_manual1.html)
3) Brodsky MB, et al. Screening accuracy for aspiration using bedside water swallow tests:A systematic review and meta-analysis. Chest. 2016;150:148-63.
4) Watando A, et al. Daily oral care and cough reflex sensitivity in elderly nursing home patients. Chest. 2004;126:1066-70.
5) Yoshino A, et al. Daily oral care and risk factors for pneumonia among elderly nursing home patients. JAMA. 2001;286:2235-6.
6) El Solh AA, et al. Pharmacologic prevention of aspiration pneumonia:a systematic review. Am J Geriatr Pharmacother. 2007;5:352-62.
7) Sekizawa K, et al. ACE inhibitors and pneumonia. Lancet. 1998;352:1069.
8) Ohkubo T, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med. 2004;169:1041-5.
9) van Vark LC, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension:a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088-97.
10) 日本高血圧学会高血圧治療ガイドライン作成委員会, 編. 高血圧治療ガイドライン2014. 東京:ライフサイエンス出版;2014.
11) Kobayashi H, et al. Levodopa and swallowing reflex. Lancet. 1996;348:1320-1.
12) Nakagawa T, et al. Amantadine and pneumonia. Lancet. 1999;353:1157.
14) Iwasaki K, et al. A pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementia. J Am Geriatr Soc. 2007;55:2035-40.
15) Teramoto S, et al. Significance of chronic cough as a defence mechanism or a symptom in elderly patients with aspiration and aspiration pneumonia. Eur Respir J. 2005;25:210-1;author reply 211.
P.164 掲載の参考文献
a) Matsuse T, et al. Importance of diffuse aspiration bronchiolitis caused by chronic occult aspiration in the elderly. Chest. 1996;110:1289-93.
b) Teramoto S. Clinical Significance of Aspiration Pneumonia and Diffuse Aspiration Bronchiolitis in the Elderly. J Gerontol Geriat Res. 2014;3:142.
c) Hu X, et al. Diffuse aspiration bronchiolitis:analysis of 20 consecutive patients. J Bras Pneumol. 2015;41:161-6.
P.171 掲載の参考文献
1) Vigeland CL, et al. Cough in idiopathic pulmonary fibrosis:more than just a nuisance. Lancet Respir Med. 2016;4:600-1.
2) Crystal RG, et al. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976;85:769-88.
3) Key AL, et al. Objective cough frequency in Idiopathic Pulmonary Fibrosis. Cough. 2010;6:4.
4) Hope-Gill BD, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:995-1002.
5) Jones RM, et al. Mechanical induction of cough in Idiopathic Pulmonary Fibrosis. Cough. 2011;7:2.
6) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会. 特発性間質性肺炎診断と治療の手引き. 改訂第3版.
7) Raghu G, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
8) Horton MR, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis:a randomized trial. Ann Intern Med. 2012;157:398-406.
9) Lutherer LO, et al. Low-dose oral interferon α possibly retards the progression of idiopathic pulmonary fibrosis and alleviates associated cough in some patients. Thorax. 2011;66:446-7.
10) Azuma A, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res. 2011;12:143.
11) Kreuter M, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis:a pooled analysis. Lancet Respir Med. 2016;4:381-9.
12) Raghu G, et al. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. Eur Respir J. 2016;48:826-32.
P.172 掲載の参考文献
1) Fletcher C, et al. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645-8.
2) 峯下昌道, 他. 喫煙が呼吸器に与える影響-50歳前後の男性自衛官における検討-. 日呼吸会誌. 2005;43:443-8.
3) Higenbottam T, et al. Lung function and symptoms of cigarette smokers related to tar yield and number of cigarettes smoked. Lancet. 1980;1:409-11.
4) Dockery DW, et al. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis. 1988;137:286-92.
5) Gilliland FD, et al. Regular smoking and asthma incidence in adolescents. Am J Respir Crit Care Med. 2006;174:1094-100.
6) Leuenberger P, et al. Passive smoking exposure in adults and chronic respiratory symptoms(SAPALDIA Study). Swiss study on air pollution and lung diseases in adults, SAPALDIA Team. Am J Respir Crit Care Med. 1994;150:1222-8.
7) Coogan PF, et al. Active and passive smoking and the incidence of asthma in the black women's health study. Am J Respir Crit Care Med. 2015;191:168-76.
8) Reh DD, et al. Secondhand tobacco smoke exposure and chronic rhinosinusitis:a population-based case-control study. Am J Rhinol Allergy. 2009;23:562-7.
P.175 掲載の参考文献
1) Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors:new insights into mechanisms and management. Curr Opin Allergy Clin Immunol. 2004;4:267-70.
2) Israili ZH, et al. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-42.
3) Morice AH, et al. Cough. 1:Chronic cough in adults. Thorax. 2003;58:901-7.
4) Furuya K, et al. Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough. Lancet. 1994;343(8893):354.
5) Li YF, et al. Angiotensin-converting enzyme(ACE)gene insertion/deletion polymorphism and ACE inhibitor-related cough:a meta-analysis. PLoS One. 2012;7:e37396.
6) Cazzola M, et al. Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough. Respiration. 1993;60:212-5.
7) Hargreaves MR, et al. Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough. Lancet. 1995;345:13-6.
8) Reitan JA, et al. Central vagal control of fentanyl-induced bradycardia during halothane anesthesia. Anesth Analg. 1978;57:31-6.
9) Yasuda I, et al. Tracheal constriction by morphine and by fentanyl in man. Anesthesiology. 1978;49:117-9.
10) Paintal AS. Mechanism of stimulation of type J pulmonary receptors. J Physiol. 1969;203:511-32.
11) Lou YP. Regulation of neuropeptide release from pulmonary capsaicin-sensitive afferents in relation to bronchoconstriction. Acta Physiol Scand Suppl. 1993;612:1-88.
12) Kim JE, et al. Pharmacological and nonpharmacological prevention of fentanyl-induced cough:a meta-analysis. J Anesth. 2014;28:257-66.
13) Li CC, et al. Fentanyl-induced cough is a risk factor for postoperative nausea and vomiting. Br J Anaesth. 2015;115:444-8.
14) Bang SR, et al. Comparison of the effectiveness of lidocaine and salbutamol on coughing provoked by intravenous remifentanil during anesthesia induction. Korean J Anesthesiol. 2010;59:319-22.
15) Salliot C, et al. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis:a systematic literature research. Ann Rheum Dis. 2009;68:1100-4.
16) Conway R, et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease:systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015;350:h1269.
17) 日本呼吸器学会. 薬剤性肺障害の診断・治療の手引き作成委員会, 編. 薬剤性肺障害の診断・治療の手引き. 東京:メディカルレビュー社;2013.
P.178 掲載の参考文献
1) Vertigan AE, et al. Somatic cough syndrome(previously referred to as psychogenic cough)and tic cough(previously referred to as habit cough)in adults and children:CHEST guideline and expert panel report. Chest. 2015;148:24-31.
2) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
3) 灰田美知子, 他. 心因性咳嗽を疑われた慢性咳嗽の代表的症例から得られた教訓. 第17回日本咳嗽研究会一般演題.
P.185 掲載の参考文献
1) Morice AH, et al. Cough hypersensitivity syndrome:a distinct clinical entity. Lung. 2011;189:73-9.
2) Morice AH, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J. 2014;44:1132-48.
3) Pavord ID, et al. Management of chronic cough. Lancet. 2008;371:1375-84.
4) Morice AH, et al. Cough hypersensitivity syndrome is an important clinical concept:a pro/con debate. Lung. 2012;190:3-9.
5) Groneberg DA, et al. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med. 2004;170:1276-80.
6) Bucca CB, et al. Chronic cough and irritable larynx. J Allergy Clin Immunol. 2011;127:412-9.
7) Gibson PG, et al. Management of chronic refractory cough. BMJ. 2015;351:h5590.
8) Morice AH, et al. A worldwide survey of chronic cough:a manifestation of enhanced somatosensory response. Eur Respir J. 2014;44:1149-55.
9) Vertigan AE, et al. A review of voice and upper airway function in chronic cough and paradoxical vocal cord movement. Curr Opin Allergy Clin Immunol. 2007;7:37-42.
10) Ryan NM, et al. Characterization of laryngeal dysfunction in chronic persistent cough. Laryngoscope. 2009;119:640-5.
11) Low K, et al. Abnormal vocal cord function in difficult-to-treat asthma. Am J Respir Crit Care Med. 2011;184:50-6.
12) Gibson PG, et al. Speech pathology for chronic cough:a new approach. Pulm Pharmacol Ther. 2009;22:159-62.
13) Idrees M, et al. Vocal cord dysfunction in bronchial asthma. A review article. J Asthma. 2015;52:327-35.
14) Pinto LH, et al. Vocal cord dysfunction diagnosis may be improved by a screening check list. Allergol Int. 2016;65:180-5.
15) Ryan NM, et al. Gabapentin for refractory chronic cough:a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:1583-9.
16) Vertigan AE, et al. Pregabalin and speech pathology combination therapy for refractory chronic cough:A randomized controlled trial. Chest. 2016;149:639-48.
17) Chung KF, et al. Chronic cough as a neuropathic disorder. Lancet Respir Med. 2013;1:414-22.
18) Jeyakumar A, et al. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope. 2006;116:2108-12.
19) Wei W, et al. The efficacy of specific neuromodulators on human refractory chronic cough:a systematic review and meta-analysis. J thorac Dis. 2016;8:2942-2951.
20) Morice AH, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175:312-5.
P.186 掲載の参考文献
a) Abdulqawi R, et al. P2X3 receptor antagonist(AF-219)in refractory chronic cough:a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015;385:1198-205.
P.188 掲載の参考文献
1) 金子公一, 他. 気管支異物:最近の症例から. 日本気管支研究会雑誌. 2006;27:518-23.
2) Baharloo F, et al. Tracheobronchial foreign bodies:presentation and management in children and adults. Chest. 1999;115:1357-62.
3) Metin B, et al. Adult foreign body aspirations treated for many years with the diagnosis of asthma:report of two cases. Acta Clin Belg. 2016;71:178-81.
5) 辻 泰佑, 他. ステロイドの先行投与とバルーンカテーテル併用により容易に除去が可能となった気管支異物の1例. 気管支学. 2014;36:487-91.
第7章 非特異的鎮咳薬
P.191 掲載の参考文献
1) Smith J, et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2006;117:831-5.
2) Freestone C, et al. Assessment of the antitussive efficacy of codeine in cough associated with common cold. J Pharm Pharmacol. 1997;49:1045-9.
3) Chang CC, et al. Over-the-counter(OTC)medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev. 2014;3:CD006088.
4) O Reilly D, et al. Cough, codeine and confusion. BMJ Case Rep. 2015;2015.
5) Ciszkowski C, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361:827-8.
P.193 掲載の参考文献
1) Morice AH, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175:312-5.
2) Bausewein C, et al. Shortness of breath and cough in patients in palliative care. Dtsch Arztebl Int. 2013;110:563-71;quiz 572.
3) Martins RT, et al. Effects of low-dose morphine on perceived sleep quality in patients with refractory breathlessness:A hypothesis generating study. Respirology. 2016;21:386-91.
4) Vozoris NT, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016;48:683-93.
P.195 掲載の参考文献
1) Nguyen L, et al. Dextromethorphan:An update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1-22.
2) Kamei J, et al. Effects of N-methyl-D-aspartate antagonists on the cough reflex. Eur J Pharmacol. 1989;168:153-8.
3) Netzer R, et al. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol. 1993;238:209-16.
4) Cummings JL, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia:A randomized clinical trial. JAMA. 2015;314:1242-54.
5) Patatanian E, et al. Dextromethorphan/quinidine for the treatment of pseudobulbar affect. Consult Pharm. 2014;29:264-9.
6) Po KT, et al. Repeated, high-dose dextromethorphan treatment decreases neurogenesis and results in depression-like behavior in rats. Exp Brain Res. 2015;233:2205-14.
7) Matthys H, et al. Dextromethorphan and codeine:objective assessment of antitussive activity in patients with chronic cough. J Int Med Res. 1983;11:92-100.
8) Aylward M, et al. Dextromethorphan and codeine:comparison of plasma kinetics and antitussive effects. Eur J Respir Dis. 1984;65:283-91.
9) Ramsay J, et al. Assessment of antitussive efficacy of dextromethorphan in smoking related cough:objective vs. subjective measures. Br J Clin Pharmacol. 2008;65:737-41.
10) Lee PCL, et al. Antitussive efficacy of dextromethorphan in cough associated with acute upper respiratory tract infection. J Pharm Pharmacol. 2000;52:1137-42.
11) Paul IM, et al. Dose-response relationship with increasing doses of dextromethorphan for children with cough. Clin Ther. 2004;26:1508-14.
P.197 掲載の参考文献
1) Ida H. The nonnarcotic antitussive drug dimemorfan:a review. Clin Ther. 1997;19:215-31.
2) Pei Q, et al. Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2015;40:427-33.
3) Shirayama Y, et al. Effects of add-on tipepidine on treatment-resistant depression:an open-label pilot trial. Acta Neuropsychiatr. 2016;28:51-4.
4) Kawaura K, et al. Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect in the forced swimming test in adrenocorticotropic hormone-treated rats. Behav Brain Res. 2016;302:269-78.
5) Sasaki T, et al. Tipepidine in children with attention deficit/hyperactivity disorder:a 4-week, open-label, preliminary study. Neuropsychiatr Dis Treat. 2014;10:147-51.
6) Haber P, et al. The bronchospasmolytic effect of eprazinone. Prax Klin Pneumol. 1985;39:54-8.
7) Levis S, et al. Evalution of the antitussive activity of some esters of pheny cycloalkane-carboxylic acids and study of different pharmacological properties of the most effective among them:The hydro-chloride of diethylaminoethoxyethyl-1-phenyl-1-cyclopentane carboxylate. Arch Int Pharmacodyn Ther. 1955;103:200-11.
8) Carter CH, et al. The clinical value of toclase in suppressing the cough reflex. Am J Med Sci. 1957;233:77-9.
9) Camisasca E, et al. Cloperastine in chronic bronchopulmonary diseases. Eur Rev Med Pharmacol Sci. 1983;5:375-8.
10) Olivieri D, et al. Clinical study of a new antitussive:cloperastine. Arch Monaldi. 1983;38:209-18.
11) Li Y, et al. Identification of some benproperine metabolites in humans and investigation of their antitussive effect. Acta Pharmacol Sin. 2005;26:1519-26.
12) Miraglia del Giudice M, et al. Controlled double-blind study on the efficacy of clofedanol-sobrerol in the treatment of pediatric pertussis. Minerva Pediatr. 1984;36:1199-206.
P.198 掲載の参考文献
a) Doona M, et al. Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med. 1998;12:55-8.
P.201 掲載の参考文献
1) Paul IM, et al. Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med. 2007;161:1140-6.
2) Cohen HA, et al. Effect of honey on nocturnal cough and sleep quality:a double-blind, randomized, placebo-controlled study. Pediatrics. 2012;130:465-71.
3) Oduwole O, et al. Honey for acute cough in children. Cochrane Database Syst Rev. 2014;12:CD007094.
4) Eccles R, et al. Mechanisms of the placebo effect of sweet cough syrups. Respir Physiol Neurobiol. 2006;152:340-8.
5) Raeessi MA, et al. Honey plus coffee versus systemic steroid in the treatment of persistent post-infectious cough:a randomised controlled trial. Prim Care Respir J. 2013;22:325-30.
P.204 掲載の参考文献
1) Hodgson D, et al. The Effects of Azithromycin in Treatment-Resistant Cough:A Randomized, Double-Blind, Placebo-Controlled Trial. Chest. 2016;149:1052-60.
2) Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013;1:262-74.
3) Rogers GB, et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis:an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2:988-96.
4) Nelson S, et al. Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung. Am Rev Respir Dis. 1987;136:1207-12.
5) Ichikawa Y, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis. 1992;146:196-203.
6) 工藤翔二, 他. びまん性汎細気管支炎にたいするエリスロマイシン少量長期投与の臨床効果に関する研究 4年間の治療成績. 本胸部疾患学会雑誌. 1997;25:632-42.
7) Nagai H, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 1991;58:145-9.
8) Altenburg J, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis:the BAT randomized controlled trial. JAMA. 2013;309:1251-9.
9) Wong C, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis(EMBRACE):a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7.
10) Serisier DJ, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis:the BLESS randomized controlled trial. JAMA. 2013;309:1260-7.
11) Uzun S, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease(COLUMBUS):a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361-8.
12) Berkhof FF, et al. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough:a randomised controlled trial. Respir Res. 2013;14:125.
13) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会, 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
14) Taylor SP. Azithromycin for the Prevention of COPD Exacerbations:The Good, Bad, and Ugly. Am J Med. 2015;128:1362. e1-6.
15) 水上絵理, 他. 咳嗽の主要原因疾患の鑑別と治療. 4)慢性気道感染症:副鼻腔気管支症候群を中心に. 呼吸器内科. 2016;29:130-5.
P.207 掲載の参考文献
1) Lim KG, et al. Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough:a case series. Chest. 2013;143:1060-5.
2) Boulet LP, et al. Airway inflammation in nonasthmatic subjects with chronic cough. Am J Respir Crit Care Med. 1994;149:482-9.
3) Evald T, et al. Chronic non-asthmatic cough is not affected by inhaled beclomethasone dipropionate. A controlled double blind clinical trial. Allergy. 1989;44:510-4.
4) Ribeiro M, et al. High-dose inhaled beclomethasone treatment in patients with chronic cough:a randomized placebo-controlled study. Ann Allergy Asthma Immunol. 2007;99:61-8.
5) Gibson P, et al. Treatment of Unexplained Chronic Cough:CHEST Guideline and Expert Panel Report. Chest. 2016;149:27-44.
6) Holmes PW, et al. Chronic persistent cough:use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med. 1992;86:425-9.
P.210 掲載の参考文献
1) 日本呼吸器学会. 咳嗽に関するガイドライン第2版作成委員会 編. 咳嗽に関するガイドライン. 第2版. 大阪:メディカルレビュー社;2012.
2) Irifune K, et al. Antitussive effect of bakumondoto a fixed kampo medicine(six herbal components)for treatment of post-infectious prolonged cough:controlled clinical pilot study with 19 patients. Phytomedicine. 2011;18:630-3.
3) 藤森勝也, 他. かぜ症候群後咳嗽に対する麦門冬湯と臭化水素酸デキストロメトルファンの効果の比較(パイロット試験). 日本東洋医学雑誌. 2001;51:725-32.
4) 渡邉直人, 他. 咳感受性の亢進している気管支喘息患者と非喘息患者に対する麦門冬湯の効果の比較検討. 日呼吸会誌. 2004;42:49-55.
5) Kim KI, et al. A traditional herbal medication, Maekmoondong-tang, for cough:A systematic review and meta-analysis. J Ethnopharmacol. 2016;178:144-54.
6) 宮本昭正, 他. TJ-19 ツムラ小青竜湯の気管支炎に対するPlacebo 対照二重盲検群間比較試験. 臨床医薬. 2001;17:1189-214.
7) 川合 満, 他. 気管支炎に対するツムラ小青竜湯の臨床効果. Ther Res. 1991;12:2617-25.
8) 長岡 滋, 他. 漢方薬の去痰作用. Mebio. 1988;5:103-8.
9) Iwasaki K, et al. The traditional Chinese medicine banxia houpo tang improves swallowing reflex. Phytomedicine. 1999;6:103-6.
10) Iwasaki K, et al. A pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementia. J Am Geriatr Soc. 2007;55:2035-40.
P.211 掲載の参考文献
1) Chamberlain Mitchell SA, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough:a multicentre randomised control trial. Thorax. 2017;72:129-36.
2) Vertigan AE, et al. Efficacy of speech pathology management for chronic cough:a randomised placebo controlled trial of treatment efficacy. Thorax. 2006;61:1065.
3) Smith JA, et al. Chronic Cough. N Engl J Med. 2016;375:1544-51.
P.212 掲載の参考文献
a) Sasieta HC, et al. Bilateral Thyroarytenoid Botulinum Toxin Type A Injection for the Treatment of Refractory Chronic Cough. JAMA Otolaryngol Head Neck Surg. 2016;142:881-8.
第8章 実際の戦略の組み立て
P.222 掲載の参考文献
1) 日本呼吸器学会. 薬剤性肺障害の診断・治療の手引き作成委員会, 編. 薬剤性肺障害の診断・治療の手引き. 大阪:メディカルレビュー社;2012.
2) Rhee CK, et al. The Korean Cough Guideline:Recommendation and summary statement. Tuberc Respir Dis(Seoul). 2016;79:14-21.
3) Irwin RS, et al. Diagnosis and management of cough executive summary:ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):1S-23S.
4) Irwin RS, et al. Overview of the management of cough:CHEST Guideline and Expert Panel Report. Chest. 2014;146:885-9.
5) Asthma Workgroup, Chinese Society, Respiratory, Diseases(CSRD), Chinese Medical, Association. The Chinese national guidelines on diagnosis and management of cough(December 2010). Chin Med J(Engl). 2011;124:3207-19.
6) 細井慶太, 他. 初診の遷延性・慢性咳嗽患者における喀痰の出現頻度の検討. 日本呼吸器学会雑誌. 2011;49(suppl. 1-1):181.
7) Gibson P, et al. Treatment of unexplained chronic cough:CHEST guideline and expert panel report. Chest. 2016;149:27-44.
P.226 掲載の参考文献
1) 日本呼吸器学会. 薬剤性肺障害の診断・治療の手引き作成委員会, 編. 薬剤性肺障害の診断・治療の手引き. 大阪:メディカルレビュー社;2012.
第9章 珍しい咳嗽たち
P.230 掲載の参考文献
1) Forsyth PA, et al. Headaches in patients with brain tumors:a study of 111 patients. Neurology. 1993;43:1678-83.
2) Lane RJ, et al. Modified Valsalva test differentiates primary from secondary cough headache. J Headache Pain. 2013;14:31.
3) Greenblatt J. Cough as a symptom of a brain tumor. Conn Med. 1961;25:239-40.
P.233 掲載の参考文献
P.235 掲載の参考文献
1) Chang CC, et al. The sick building syndrome. I. Definition and epidemiological considerations. J Asthma. 1993;30:285-95.
2) 厚生労働科学研究(健康安全・危機管理対策総合研究事業). シックハウス症候群診療マニュアル.
3) Niles JK, et al. Comorbid trends in World Trade Center cough syndrome and probable posttraumatic stress disorder in firefighters. Chest. 2011;140:1146-54.
4) 日本精神神経学会, 監. DSM-5 精神疾患の診断・統計マニュアル. 東京:医学書院;2014.
最近チェックした商品履歴
Loading...